• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
Trade NameT SPOT-TB TEST
Classification Namemycobacterium tuberculosis, cell mediated immune response, enzyme-linked immunospot test
ApplicantOXFORD IMMUNOTEC,LTD.
PMA NumberP070006
Date Received02/06/2007
Decision Date07/30/2008
Product Code
OJN[ Registered Establishments with OJN ]
Docket Number 08M-0477
Notice Date 08/26/2008
Advisory Committee Microbiology
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the t-spot-tb. This device is indicated for use as an in vitro diagnostic test for the detection of effector t cells that respond to stimulation by mycobacterium tuberculosis antigens esat-6 and cfp-10 by capturing interferon gamma (ifn-¿) in the vicinity of t cells in human whole blood collected in sodium citrate or sodium or lithium heparin. It is intended for use as an aid in the diagnosis of m. Tuberculosis infection. T-spot-tb is an indirect test for m. Tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography and other medical and diagnostic evaluations.
Approval Order Approval Order
Supplements: S001 S002 S003 S004 S005 S006 S007 S008 S009 
S011 
-
-